PORTFOLIO NEWS ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics October 23, 2024 Read More » Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM October 17, 2024 Read More » Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor CID-078 for advanced solid tumors October 15, 2024 Read More » Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor October 15, 2024 Read More » Circle Pharma and Boehringer Ingelheim announce new research collaboration to develop a novel precision cancer treatment October 9, 2024 Read More » Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney October 7, 2024 Read More » Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO October 7, 2024 Read More » Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration September 24, 2024 Read More » Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million September 17, 2024 Read More » Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate September 10, 2024 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics October 23, 2024 Read More »
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM October 17, 2024 Read More »
Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor CID-078 for advanced solid tumors October 15, 2024 Read More »
Atavistik Bio Announces Nomination of Precision Oncology Development Candidate, ATV-1601, a Selective Allosteric AKT1 E17K Small Molecule Inhibitor October 15, 2024 Read More »
Circle Pharma and Boehringer Ingelheim announce new research collaboration to develop a novel precision cancer treatment October 9, 2024 Read More »
Judo Bio Unveils Data Demonstrating Receptor-mediated Delivery of Oligonucleotides to the Kidney October 7, 2024 Read More »
Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO October 7, 2024 Read More »
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration September 24, 2024 Read More »
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million September 17, 2024 Read More »
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate September 10, 2024 Read More »
